Predicting Immunotherapy Response – The Importance of Overlooked B Cells

When researcher Dr. Florent Petitprez began investigating why some patients with soft tissue cancer (sarcoma) survived longer than others, he expected the answer to come from T lymphocytes.
T cells have been more extensively studied in the field of immunotherapy, which means using the immune system against cancer, and more research has been conducted on these cells.
Dr. Petitprez analyzed the results of a study recently published in Nature, the medical journal, which included detailed genomic analyses of tumors, and noticed a striking finding: in patients with sarcoma who had longer survival, the tumor microenvironment contained specific lymphoid structures formed by immune cells gathering together (called tertiary lymphoid structures), with strong B cell signatures.
Dr. Wargo, one of the leading figures in the study, and colleagues had shown in their previous research that in high-risk, resectable (surgically removable) metastatic melanoma, administering immunotherapy before surgery resulted in better success rates. Stronger B cell signatures in patients with better response rates to immunotherapy were also observed, they had reported.
In another study, Dr. Wargo and the team studied melanoma and renal cell carcinoma (kidney cancer) using bulk RNA sequencing (sequence analysis), finding that patients treated with immune checkpoint inhibitors as immunotherapies who had high response rates also had high levels of B cell markers.
They suggested that B cells function within the tumor in the tertiary lymphoid structures mentioned above, which resemble lymph nodes, by producing antibodies and various signals that make T cells more active.
Wargo states that the replication of these observations in studies conducted around the world supports the findings and provides evidence that this is not a coincidence.
In the group of patients with advanced sarcoma who had a good prognosis (disease course), pembrolizumab-mediated PD-1 blockade was again found to be greater in a phase 2 clinical trial. A study in patients with metastatic melanoma also reported that both T cells and B cells were associated with longer survival.
In this context, the studies discussed above, by addressing the relationship between T and B cells in cancer immunotherapy, show promise for future treatments. Dr. Petitrez's published article is one of a trio of studies published in the medical journal Nature in early 2020. Together, the points raised by Dr. Petitrez may help us better understand the role of B cells, which have so far been less extensively studied in immunotherapy, and shed light on why responses to immunotherapies are observed in only 20% to 30% of patients, potentially giving rise to new and effective treatment approaches, particularly for cancers such as sarcomas, renal cell carcinomas (kidney cancer) and malignant melanoma.
Sources
2. Helmink BA, Reddy SM, Gao J et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555.
3. ClinicalTrials.gov. Sarcoma Alliance for Research through Collaboration. (2014). SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas. NCT02301039. https://clinicaltrials.gov/ct2/show/NCT02301039. Accessed February 25, 2020.
4. Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565.
5. https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/b-cells-immunotherapy-cancer-response-evidence-suggests/ Accessed February 25, 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.